Provention Bio Inc., an Oldwick-based biopharmaceutical company, has named a new chief commercial officer, it announced Wednesday.
Provention Bio, which is a clinical-stage firm aiming to intercept and prevent immune-mediated diseases, said Jason Hoitt will now serve as its CCO. Hoitt, who has 18 years of commercial experience in the biotechnology sector, will be part of the senior leadership team, responsible for development and execution of the company’s global commercial strategy for its teplizumab product, PRV-031.
“We welcome Jason to our executive leadership team as we continue to advance PRV-031 toward the market, begin to build our commercial capabilities and continue to evaluate potential partnerships for all indications and geographies,” CEO Ashleigh Palmer said in a prepared statement. “Jason’s extensive commercial experience, including the planning, preparation and execution of product launches in rare diseases and nascent markets, will be critical as we work to bring teplizumab to Type 1 diabetes patients and at-risk individuals and, in parallel, advance our business development efforts for teplizumab.”
Hoitt most recently was chief commercial officer for Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum AB. He has also worked in leadership roles at Insmed Inc., Sarepta Therapeutics, Vertex Pharmaceuticals and others.